Precision BioSciences to Present Preclinical Data on Hepatitis B Treatment at EASL Congress
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies, today announced that the company w
Express News | Precision Biosciences presented new clinical safety data for Pbgene-Hbv candidate at the European Liver Research Association Conference.
Express News | Precision BioSciences Inc: Ind and/or Cta on-Track for Submission in 2024
Express News | Precision BioSciences Inc: Pbgene-Hbv Was Well Tolerated Across Multiple Administrations With No off-Target Editing Observed
Express News | Precision BioSciences Presents New Preclinical Safety Data for Pbgene-Hbv Clinical Candidate at the European Association for the Study of the Liver Congress
HC Wainwright & Co. : The Precision BioSciences (DTIL.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $60.00 to $60.00.
HC Wainwright & Co. : The Precision BioSciences (DTIL.US) rating was reaffirmed, adjusted from buy to buy rating, and the target price was adjusted from $60.00 to $60.00.
Precision BioSciences to Participate in Upcoming June Investor Conferences
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Buy Rating on Precision BioSciences: Leading the Way in Gene Editing for Chronic Hepatitis B
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Register Stunning Growth by 2032, Predicts DelveInsight | Key Companies - AUTOLUS THERAPEUTICS, CELLECTIS, WUGEN, SERVIER, ALLOGENE, PRECISION BIOSCIENCES
The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22, WU-C
Buy Rating Affirmed for Precision BioSciences on Strong Pipeline and Market Potential
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene
Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Precision Biosciences Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
HC Wainwright & Co. : Reiterated Precision BioSciences (DTIL.US) rating, adjusted from buy to buy rating, target price of $60.00.
HC Wainwright & Co. : Reiterated Precision BioSciences (DTIL.US) rating, adjusted from buy to buy rating, target price of $60.00.
HC Wainwright & Co. Reiterates Buy on Precision BioSciences, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Precision BioSciences with a Buy and maintains $60 price target.
Precision BioSciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/16/2024 395.87% HC Wainwright & Co. → $60 Reiterates Buy → Buy 04/30/2024 57.02% Guggenheim → $19 Initi
Analysts Offer Insights on Healthcare Companies: Precision BioSciences (DTIL) and Adicet Bio (ACET)
Maintaining Hold on Precision BioSciences Pending Clinical Data and Strategic Reassessments
Buy Rating Affirmed for Precision BioSciences on Advancing Gene Editing Pipeline and Strong Financials
Quarterly Results Takes Precision BioSciences Higher
Precision BioSciences Reports Profit From Cont. Ops. In Q1